Oragenics Inc (OGEN)

$1.32 +0.04 (3.13%)
Market Cap 5.28M
Revenue (ttm) 0.00
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 37,800
Avg Vol 162,002
Day's Range N/A - N/A
Shares Out 4.13M
Stochastic %K 35%
Beta 0.83
Analysts Strong Buy
Price Target $2.00

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplif...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 286 7900
Fax: 813 286 7900
Address:
1990 Main Street, Suite 750, Sarasota, United States
NMax
NMax Oct. 24 at 7:32 PM
$OGEN @Dh15708 agreed. PR soon
0 · Reply
NMax
NMax Oct. 24 at 2:40 PM
$OGEN Excited to load up next week! 😁 Have a great weekend! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Oct. 24 at 1:06 PM
$OGEN compliance boards need to start looking at the narrative of what these companies are accomplishing. A decade was a long enough period of time for Oragenics to prove viability, and it has nothing to show for that time period. No products, no services. It's time to dissolve as an incorporated entity because further operation has just led to scams and fraud. If you invest money here, it will go to Janet's salary and board compensation.
1 · Reply
RocketQueen
RocketQueen Oct. 23 at 10:14 PM
$OGEN this is a failed company that has never produced anything. Compliance just means more scams and ripoffs for those unaware of how these companies take advantage of corporate loopholes, dubious market enabling practices and substandard business practices. They have no offices, no labs, no working employees and no viable products.
0 · Reply
NMax
NMax Oct. 23 at 7:50 PM
$OGEN $GME Soulbound. Continuing to accumulate! Excited for the future! Patience 😎
1 · Reply
simplifocused
simplifocused Oct. 23 at 3:27 PM
$OGEN NFA Oragenics Regains NYSE Compliance After Public Offering https://www.tipranks.com/news/company-announcements/oragenics-regains-nyse-compliance-after-public-offering?utm_source=webullapp.com&utm_medium=referral
0 · Reply
simplifocused
simplifocused Oct. 23 at 2:48 PM
$OGEN NFA, can shock everyone like $BYND $DRUG https://stockscan.io/stocks/OGEN/forecast
0 · Reply
NMax
NMax Oct. 23 at 2:13 PM
$OGEN happy to continue adding here. 🤑🤑🤑
0 · Reply
sincosine
sincosine Oct. 23 at 1:23 PM
$OGEN
0 · Reply
markusann
markusann Oct. 22 at 7:42 PM
$OGEN just laid a fart on this stock
1 · Reply
Latest News on OGEN
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oct 21, 2025, 8:00 AM EDT - 4 days ago

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oct 7, 2025, 8:30 AM EDT - 18 days ago

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Oragenics Q2 2025 Shareholder Update

Aug 11, 2025, 8:45 AM EDT - 2 months ago

Oragenics Q2 2025 Shareholder Update

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 16, 2025, 8:39 AM EDT - 3 months ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Oragenics Completes Approximately $16.5 Million Offering

Jul 2, 2025, 4:15 PM EDT - 4 months ago

Oragenics Completes Approximately $16.5 Million Offering

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Jul 1, 2025, 8:31 AM EDT - 4 months ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025, 8:30 AM EDT - 5 months ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025, 8:30 AM EDT - 5 months ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Apr 7, 2025, 4:30 PM EDT - 7 months ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 27, 2025, 8:30 AM EDT - 7 months ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 18, 2025, 5:33 PM EDT - 7 months ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Mar 6, 2025, 9:30 AM EST - 8 months ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 25, 2025, 8:30 AM EST - 8 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 11, 2025, 8:30 AM EST - 9 months ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Feb 5, 2025, 8:15 AM EST - 9 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Jan 21, 2025, 8:15 AM EST - 9 months ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Dec 16, 2024, 8:09 AM EST - 11 months ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. Announces Closing of Public Offering

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 16, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Aug 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Proposed Public Offering

Jun 24, 2024, 6:43 PM EDT - 1 year ago

Oragenics, Inc. Announces Proposed Public Offering

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024, 8:00 AM EDT - 1 year ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024, 8:00 AM EDT - 1 year ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 19, 2024, 5:50 PM EDT - 1 year ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024, 9:05 AM EDT - 1 year ago

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 5, 2024, 7:45 AM EST - 1 year ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Mar 1, 2024, 4:04 PM EST - 1 year ago

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 9:25 PM EST - 1 year ago

Oragenics Announces Pricing of Public Offering

Oragenics Announces Proposed Public Offering

Feb 27, 2024, 4:33 PM EST - 1 year ago

Oragenics Announces Proposed Public Offering

Oragenics, Inc. Announces Leadership Transition

Feb 12, 2024, 4:41 PM EST - 1 year ago

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Feb 7, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Feb 5, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Termination of At-The-Market Offering Program

Jan 23, 2024, 5:34 PM EST - 1 year ago

Oragenics Announces Termination of At-The-Market Offering Program

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Jan 2, 2024, 7:30 AM EST - 1 year ago

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Oragenics Issues Update to Shareholders

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Oragenics Issues Update to Shareholders

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oct 5, 2023, 6:30 AM EDT - 2 years ago

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Sep 29, 2023, 4:00 PM EDT - 2 years ago

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Oragenics, Inc. Announces Private Placement

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Oragenics, Inc. Announces Private Placement

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Jun 5, 2023, 4:18 PM EDT - 2 years ago

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

NMax
NMax Oct. 24 at 7:32 PM
$OGEN @Dh15708 agreed. PR soon
0 · Reply
NMax
NMax Oct. 24 at 2:40 PM
$OGEN Excited to load up next week! 😁 Have a great weekend! 🤑🤑🤑
0 · Reply
RocketQueen
RocketQueen Oct. 24 at 1:06 PM
$OGEN compliance boards need to start looking at the narrative of what these companies are accomplishing. A decade was a long enough period of time for Oragenics to prove viability, and it has nothing to show for that time period. No products, no services. It's time to dissolve as an incorporated entity because further operation has just led to scams and fraud. If you invest money here, it will go to Janet's salary and board compensation.
1 · Reply
RocketQueen
RocketQueen Oct. 23 at 10:14 PM
$OGEN this is a failed company that has never produced anything. Compliance just means more scams and ripoffs for those unaware of how these companies take advantage of corporate loopholes, dubious market enabling practices and substandard business practices. They have no offices, no labs, no working employees and no viable products.
0 · Reply
NMax
NMax Oct. 23 at 7:50 PM
$OGEN $GME Soulbound. Continuing to accumulate! Excited for the future! Patience 😎
1 · Reply
simplifocused
simplifocused Oct. 23 at 3:27 PM
$OGEN NFA Oragenics Regains NYSE Compliance After Public Offering https://www.tipranks.com/news/company-announcements/oragenics-regains-nyse-compliance-after-public-offering?utm_source=webullapp.com&utm_medium=referral
0 · Reply
simplifocused
simplifocused Oct. 23 at 2:48 PM
$OGEN NFA, can shock everyone like $BYND $DRUG https://stockscan.io/stocks/OGEN/forecast
0 · Reply
NMax
NMax Oct. 23 at 2:13 PM
$OGEN happy to continue adding here. 🤑🤑🤑
0 · Reply
sincosine
sincosine Oct. 23 at 1:23 PM
$OGEN
0 · Reply
markusann
markusann Oct. 22 at 7:42 PM
$OGEN just laid a fart on this stock
1 · Reply
profitingstocks
profitingstocks Oct. 22 at 6:38 PM
$OGEN that’s compliance sorted for a bit longer, now they just need to hire their first working employee, open up a physical headquarters, create the company’s first product, generate the first $1 in revenue in the company’s history, reduce the the >$10M per year losses, and try not to use any more of the 350,000,000 authorised shares on toxic financing and dilution… Sort all that out and we may just see $2 one day!
0 · Reply
XAMN
XAMN Oct. 22 at 6:25 PM
$OGEN The @RocketQueen account should be investigated for manipulation of a security. Noones selling ya dingus 🤗
0 · Reply
XAMN
XAMN Oct. 22 at 6:20 PM
$OGEN
0 · Reply
RocketQueen
RocketQueen Oct. 22 at 4:13 PM
$OGEN listing won't help because capital raises are going to send this back down to twenty cents range---which will lead to another R/S. More scams and fraud.
0 · Reply
NMax
NMax Oct. 22 at 1:21 PM
$OGEN continuing to accumulate 🤑🤑🤑
1 · Reply
Dh15708
Dh15708 Oct. 22 at 10:57 AM
$OGEN early premarket.another pr?
0 · Reply
XAMN
XAMN Oct. 22 at 3:40 AM
$OGEN over half a year of these idiotic posts by @RocketQueen (who supposedly sold back in March) telling us this would be delisted due to non-compliance on October 17th. Who spend this much time and energy on something they're not invested in 🤣 Really quite weird.
0 · Reply
XAMN
XAMN Oct. 22 at 3:34 AM
$OGEN
0 · Reply
RocketQueen
RocketQueen Oct. 22 at 3:10 AM
$OGEN if you are new to OGEN, the company is a scam and fraud that takes advantage of corporate loopholes and market vulnerabilities to stay in business and ripoff retail investors. Their all time stock chart shoes -25,000 in stock price drop or 99.99%. If you invest here, you will lose money. Bearish
0 · Reply
simplifocused
simplifocused Oct. 21 at 9:28 PM
$OGEN Oragenics Regains Nasdaq Compliance Benzinga · 10/21/2025 13:01 NFA
0 · Reply
XAMN
XAMN Oct. 21 at 8:36 PM
$OGEN boy we got a lot of material showing that you're the fraud here @RocketQueen 🤣
0 · Reply
XAMN
XAMN Oct. 21 at 8:26 PM
$OGEN $PLXPQ
1 · Reply